Viking Therapeutics (VKTX) Change in Account Payables (2014 - 2026)

Viking Therapeutics has disclosed Change in Account Payables across 13 years of filings, most recently posting $13.9 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $13.9 million, up 760.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.5 million (up 2298.35% YoY), and the FY2025 annual result was $43.4 million, up 1786.15% from the prior year.
• Change in Account Payables came in at $13.9 million for Q1 2026 at Viking Therapeutics, down from $48.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $48.8 million in Q4 2025 to a low of -$10.8 million in Q3 2024.
• The 5-year median for Change in Account Payables is $1.7 million (2022), against an average of $3.9 million.
• Across the five-year window, Change in Account Payables plunged 10935.0% in 2024 and soared 760.24% in 2026, its largest moves.
• Viking Therapeutics' Change in Account Payables stood at $5.4 million in 2022, then plunged by 66.57% to $1.8 million in 2023, then surged by 430.87% to $9.6 million in 2024, then soared by 410.8% to $48.8 million in 2025, then tumbled by 71.48% to $13.9 million in 2026.
• The last three Change in Account Payables figures came in at $13.9 million (Q1 2026), $48.8 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.